Biologics Brief: E1 How to Choose a CRO for Antibody Discovery

Published: May 28, 2026 | Category: Insights

---

Outsourcing antibody discovery is one of the most capital-efficient decisions an early-stage biotech can make. Building the lab, the equipment, and the team to do it in-house is slow and expensive, and the expertise you need already exists, on demand, at a fraction of the cost. But the value you actually get out of a CRO depends almost entirely on which partner you choose, and on the questions you ask before you sign.

In the first episode of The Biologics Brief, Mosaic CSO Eric Furfine sat down with Mara Sprouse to talk through how to evaluate a preclinical CRO for an antibody discovery program, what separates a real partner from a vendor, and where buyers most often get burned. Here’s the practical version.

---

Start With the Target Clinical Profile

The single decision that should drive everything else is the target clinical profile, what you want the molecule to do in the clinic. Once that’s clear, you can design the preclinical work to give yourself the best possible chance of getting there.

This is also the first test of whether a CRO is right for you. A good partner digs into the details of what your medicine needs to do before they recommend a technology. If a CRO leads with its platform instead of your goals, that’s backwards. The science should follow the clinical profile, not the other way around.

---

Why Biotechs Outsource Discovery in the First Place

Two reasons dominate, and they apply across the industry, not just to early-stage companies, but to large pharma and virtual biotechs alike.

The first is capital efficiency. Standing up a discovery organization from scratch, hiring scientists, securing lab space, buying and validating equipment, training, equity, is a substantial investment, and you often end up with a team less practiced in the craft than one that does this work every day for many partners. When that capability is already commercially available for less than you could build it yourself, building it rarely makes sense.

The second is speed. In a funding environment this tight, speed is everything. A CRO with deep, repeatable expertise can start immediately. And a disease-agnostic CRO brings an additional edge: working across indications means lessons from one disease area can be applied to yours, a depth of experience you simply can’t get by hiring a few individual scientists.

---

What “Fully Integrated” Actually Means

“Fully integrated” gets used loosely, so it’s worth being specific. Discovering an antibody sequence is the beginning, not the end. The biology still has to be proven. Knowledge has to move from the people who discovered the molecule to the people running pharmacology, the people running stability studies, and eventually the people handling manufacturing.

The advantage of an integrated, end-to-end CRO is that those handoffs aren’t handoffs at all. The teams have worked together before, they know each other, and they’re motivated to share what they learned along the way. That continuity is what raises your probability of success, far more than any single assay or platform does in isolation.

---

The Price Trap: Know What You’re Buying

Antibody discovery is a competitive market, and you will see attractive prices. Two cautions before you anchor on the lowest one.

First, make sure you’re comparing the same thing. A low quote often takes you a shorter distance down the road than you assume. When the work is “done,” you may discover a stack of additional steps still standing between you and an actual antibody, work you now have to source elsewhere, with no guarantee the earlier foundation was built correctly.

Second, ask how much testing the CRO actually does to confirm the molecules they identify have the properties you need. Sequences alone don’t tell you much. Does the antibody bind the target? Does it do the biology you need it to do? A comprehensive workflow that gets you to a functional answer usually carries a higher price tag, and delivers far more in return.

---

The Questions to Ask Before You Sign

A few questions cut through most of the noise:

• What are the campaign deliverables? Are you getting sequences, recombinant protein, characterization, developability, or just hits?

• What does the cost look like beyond the first decision point? Understand what it takes to reach a true lead candidate, not just an initial milestone.

• Have you worked on difficult targets, and can you show me the data? Targets are only getting harder. Experience and evidence matter.

• Who will actually run my program? Senior and principal scientists, or is the data going to be lobbed over the fence for you to interpret alone? (For context, roughly 80% of Mosaic’s scientists hold advanced degrees in biochemistry, immunology, protein sciences, or chemistry.)

• Can you explain the pros and cons of your different discovery platforms for my target? A strong partner can look at your target and tell you what they’d recommend, why, and what the trade-offs are.

---

What Happens When a Campaign Doesn’t Deliver

Not every campaign yields what you hoped, some targets are genuinely hard. The thing to establish up front is the minimum product your CRO will deliver for the investment, and what reasonable next experiments exist if the first round comes up short.

Often the smartest move is to map this out before you start: here’s the first approach, here’s what we’d try next if it doesn’t work, and here’s the round after that. Whether you throw everything at the target at once or proceed more linearly is a cost-and-speed decision, but either way, a good partner helps you understand why something didn’t work and where the data points you next. That drug-hunter judgment, applied to a campaign that stalled, is often worth more than the original plan.

---

The throughline across all of it is the same: price and speed matter, but fit matters more. The right partner understands what you’re trying to achieve clinically, builds a plan to get you there, and stays in the work alongside you, like an extension of your own team.

View and listen to the full video conversation on The Biologics Brief. Episode two covers transgenic mice and other antibody discovery platforms.

---